Clinical Trial Update: Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients [Phase 2]

View source ↗

Summary

An extension Phase 2 study evaluating long-term safety and tolerability of repeat doses of FE200486 in prostate cancer patients was terminated; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• FE200486

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2009-06-12